Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 72

1.

Pattern of failure in anaplastic glioma patients with an IDH1/2 mutation.

Back M, Jayamanne D, Brazier D, Newey A, Bailey D, Schembri G, Hsiao E, Khasraw M, Wong M, Kastelan M, Brown C, Wheeler H.

Strahlenther Onkol. 2019 Apr 26. doi: 10.1007/s00066-019-01467-0. [Epub ahead of print]

PMID:
31028406
2.

Anticonvulsant prophylaxis and steroid use in adults with metastatic brain tumors: summary of SNO and ASCO endorsement of the Congress of Neurological Surgeons guidelines.

Chang SM, Messersmith H, Ahluwalia M, Andrews D, Brastianos PK, Gaspar LE, Gatson NN, Jordan JT, Khasraw M, Lassman AB, Maues J, Mrugala M, Raizer J, Schiff D, Stevens G, Sumrall A, Van den Bent M, Vogelbaum MA.

Neuro Oncol. 2019 Mar 18;21(4):424-427. doi: 10.1093/neuonc/noz034.

PMID:
30883663
3.

Anticonvulsant Prophylaxis and Steroid Use in Adults With Metastatic Brain Tumors: ASCO and SNO Endorsement of the Congress of Neurological Surgeons Guidelines.

Chang SM, Messersmith H, Ahluwalia M, Andrews D, Brastianos PK, Gaspar LE, Gatson NTN, Jordan JT, Khasraw M, Lassman AB, Maues J, Mrugala M, Raizer J, Schiff D, Stevens G, Sumrall A, van den Bent M, Vogelbaum MA.

J Clin Oncol. 2019 May 1;37(13):1130-1135. doi: 10.1200/JCO.18.02085. Epub 2019 Mar 18.

PMID:
30883246
4.

Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor (MIF).

Ha W, Sevim-Nalkiran H, Zaman AM, Matsuda K, Khasraw M, Nowak AK, Chung L, Baxter RC, McDonald KL.

Sci Rep. 2019 Feb 27;9(1):2905. doi: 10.1038/s41598-019-39427-4.

5.

Tailored NEOadjuvant epirubicin, cyclophosphamide and Nanoparticle Albumin-Bound paclitaxel for breast cancer: The phase II NEONAB trial-Clinical outcomes and molecular determinants of response.

Murphy C, Muscat A, Ashley D, Mukaro V, West L, Liao Y, Chisanga D, Shi W, Collins I, Baron-Hay S, Patil S, Lindeman G, Khasraw M.

PLoS One. 2019 Feb 14;14(2):e0210891. doi: 10.1371/journal.pone.0210891. eCollection 2019.

6.

Influence of molecular classification in anaplastic glioma for determining outcome and future approach to management.

Back M, Jayamanne DT, Brazier D, Newey A, Bailey D, Schembri GP, Hsiao E, Khasraw M, Wong M, Kastelan M, Guo L, Clarke S, Wheeler H.

J Med Imaging Radiat Oncol. 2019 Apr;63(2):272-280. doi: 10.1111/1754-9485.12850. Epub 2019 Jan 24.

PMID:
30677248
7.

Anti-angiogenic therapy for high-grade glioma.

Ameratunga M, Pavlakis N, Wheeler H, Grant R, Simes J, Khasraw M.

Cochrane Database Syst Rev. 2018 Nov 22;11:CD008218. doi: 10.1002/14651858.CD008218.pub4.

PMID:
30480778
8.

Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study.

Shapiro JD, Thavaneswaran S, Underhill CR, Robledo KP, Karapetis CS, Day FL, Nott LM, Jefford M, Chantrill LA, Pavlakis N, Tebbutt NC, Price TJ, Khasraw M, Van Hazel GA, Waring PM, Tejpar S, Simes J, Gebski VJ, Desai J, Segelov E.

Clin Colorectal Cancer. 2018 Dec;17(4):313-319. doi: 10.1016/j.clcc.2018.06.002. Epub 2018 Jun 8.

PMID:
30463680
9.

Optimising Outcomes for Glioblastoma through Subspecialisation in a Regional Cancer Centre.

Back M, Jayamanne D, Cove N, Wheeler H, Khasraw M, Guo L, Back J, Wong M.

Brain Sci. 2018 Oct 15;8(10). pii: E186. doi: 10.3390/brainsci8100186.

10.

Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours.

Raymond E, Kulke MH, Qin S, Yu X, Schenker M, Cubillo A, Lou W, Tomasek J, Thiis-Evensen E, Xu JM, Croitoru AE, Khasraw M, Sedlackova E, Borbath I, Ruff P, Oberstein PE, Ito T, Jia L, Hammel P, Shen L, Shrikhande SV, Shen Y, Sufliarsky J, Khan GN, Morizane C, Galdy S, Khosravan R, Fernandez KC, Rosbrook B, Fazio N.

Neuroendocrinology. 2018;107(3):237-245. doi: 10.1159/000491999. Epub 2018 Jul 10.

PMID:
29991024
11.

Correction to: Geographic region, socioeconomic position and the utilisation of primary total joint replacement for hip or knee osteoarthritis across western Victoria: a cross-sectional multilevel study of the Australian Orthopaedic Association National Joint Replacement Registry.

Brennan-Olsen S, Vogrin S, Holloway KL, Page RS, Sajjad MA, Kotowicz MA, Livingston PM, Khasraw M, Hakkennes S, Dunning TL, Brumby S, Pedler D, Sutherland A, Venkatesh S, Williams LJ, Duque G, Graves S, Lorimer M, Pasco JA.

Arch Osteoporos. 2018 Jul 9;13(1):75. doi: 10.1007/s11657-018-0484-y.

PMID:
29987672
12.

Understanding the Revised Fourth Edition of the World Health Organization Classification of Tumours of the Central Nervous System (2016) for Clinical Decision-making: A Guide for Oncologists Managing Patients with Glioma.

Back M, Rodriguez M, Jayamanne D, Khasraw M, Lee A, Wheeler H.

Clin Oncol (R Coll Radiol). 2018 Sep;30(9):556-562. doi: 10.1016/j.clon.2018.06.005. Epub 2018 Jul 3.

PMID:
29980381
13.

Profiles of brain metastases: Prioritization of therapeutic targets.

Ferguson SD, Zheng S, Xiu J, Zhou S, Khasraw M, Brastianos PK, Kesari S, Hu J, Rudnick J, Salacz ME, Piccioni D, Huang S, Davies MA, Glitza IC, Heymach JV, Zhang J, Ibrahim NK, DeGroot JF, McCarty J, O'Brien BJ, Sawaya R, Verhaak RGW, Reddy SK, Priebe W, Gatalica Z, Spetzler D, Heimberger AB.

Int J Cancer. 2018 Dec 1;143(11):3019-3026. doi: 10.1002/ijc.31624. Epub 2018 Oct 9.

14.

Utilizing 18F-fluoroethyltyrosine (FET) positron emission tomography (PET) to define suspected nonenhancing tumor for radiation therapy planning of glioblastoma.

Hayes AR, Jayamanne D, Hsiao E, Schembri GP, Bailey DL, Roach PJ, Khasraw M, Newey A, Wheeler HR, Back M.

Pract Radiat Oncol. 2018 Jul - Aug;8(4):230-238. doi: 10.1016/j.prro.2018.01.006. Epub 2018 Jan 31.

PMID:
29730279
15.

The evolutionary pattern of mutations in glioblastoma reveals therapy-mediated selection.

Muscat AM, Wong NC, Drummond KJ, Algar EM, Khasraw M, Verhaak R, Field K, Rosenthal MA, Ashley DM.

Oncotarget. 2017 Dec 15;9(8):7844-7858. doi: 10.18632/oncotarget.23541. eCollection 2018 Jan 30.

16.

Outcomes after second surgery for recurrent glioblastoma: a retrospective case-control study.

Wann A, Tully PA, Barnes EH, Lwin Z, Jeffree R, Drummond KJ, Gan H, Khasraw M.

J Neurooncol. 2018 Apr;137(2):409-415. doi: 10.1007/s11060-017-2731-2. Epub 2018 Jan 2.

PMID:
29294233
17.

The epidemiology of hip fractures across western Victoria, Australia.

Holloway KL, Sajjad MA, Mohebbi M, Kotowicz MA, Livingston PM, Khasraw M, Hakkennes S, Dunning TL, Brumby S, Page RS, Pedler D, Sutherland A, Venkatesh S, Brennan-Olsen SL, Williams LJ, Pasco JA.

Bone. 2018 Mar;108:1-9. doi: 10.1016/j.bone.2017.12.007. Epub 2017 Dec 8.

PMID:
29229437
18.

Geographic region, socioeconomic position and the utilisation of primary total joint replacement for hip or knee osteoarthritis across western Victoria: a cross-sectional multilevel study of the Australian Orthopaedic Association National Joint Replacement Registry.

Brennan-Olsen S, Vogrin S, Holloway KL, Page RS, Sajjad MA, Kotowicz MA, Livingston PM, Khasraw M, Hakkennes S, Dunning TL, Brumby S, Pedler D, Sutherland A, Venkatesh S, Williams LJ, Duque G, Pasco JA.

Arch Osteoporos. 2017 Nov 6;12(1):97. doi: 10.1007/s11657-017-0396-2. Erratum in: Arch Osteoporos. 2018 Jul 9;13(1):75.

PMID:
29110097
19.

Patient-reported experience of the impact and burden of neuroendocrine tumors: Oceania patient results from a large global survey.

Leyden J, Pavlakis N, Chan D, Michael M, Clarke S, Khasraw M, Price T.

Asia Pac J Clin Oncol. 2018 Jun;14(3):256-263. doi: 10.1111/ajco.12785. Epub 2017 Nov 6.

PMID:
29105989
20.

Evaluating the role of magnetic resonance imaging post-neoadjuvant therapy for breast cancer in the NEONAB trial.

Murphy C, Mukaro V, Tobler R, Asher R, Gibbs E, West L, Giuffre B, Baron-Hay S, Khasraw M.

Intern Med J. 2018 Jun;48(6):699-705. doi: 10.1111/imj.13617.

PMID:
28869790
21.

Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE.

Alexander BM, Ba S, Berger MS, Berry DA, Cavenee WK, Chang SM, Cloughesy TF, Jiang T, Khasraw M, Li W, Mittman R, Poste GH, Wen PY, Yung WKA, Barker AD; GBM AGILE Network.

Clin Cancer Res. 2018 Feb 15;24(4):737-743. doi: 10.1158/1078-0432.CCR-17-0764. Epub 2017 Aug 16. Review.

22.

Combination of palbociclib and radiotherapy for glioblastoma.

Whittaker S, Madani D, Joshi S, Chung SA, Johns T, Day B, Khasraw M, McDonald KL.

Cell Death Discov. 2017 Jul 3;3:17033. doi: 10.1038/cddiscovery.2017.33. eCollection 2017.

23.

Survival Outcomes of Elderly Patients With Glioblastoma Multiforme in Their 75th Year or Older Treated With Adjuvant Therapy.

Harris G, Jayamanne D, Wheeler H, Gzell C, Kastelan M, Schembri G, Brazier D, Cook R, Parkinson J, Khasraw M, Louw S, Back M.

Int J Radiat Oncol Biol Phys. 2017 Jul 15;98(4):802-810. doi: 10.1016/j.ijrobp.2017.02.028. Epub 2017 Feb 21.

PMID:
28602411
24.

Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance.

Chan DL, Pavlakis N, Schembri GP, Bernard EJ, Hsiao E, Hayes A, Barnes T, Diakos C, Khasraw M, Samra J, Eslick E, Roach PJ, Engel A, Clarke SJ, Bailey DL.

Theranostics. 2017 Mar 1;7(5):1149-1158. doi: 10.7150/thno.18068. eCollection 2017.

25.

Immune Checkpoint Inhibitors for Brain Metastases.

Tan AC, Heimberger AB, Menzies AM, Pavlakis N, Khasraw M.

Curr Oncol Rep. 2017 Jun;19(6):38. doi: 10.1007/s11912-017-0596-3. Review.

PMID:
28417311
26.

Veliparib in combination with radiotherapy for the treatment of MGMT unmethylated glioblastoma.

Jue TR, Nozue K, Lester AJ, Joshi S, Schroder LB, Whittaker SP, Nixdorf S, Rapkins RW, Khasraw M, McDonald KL.

J Transl Med. 2017 Mar 17;15(1):61. doi: 10.1186/s12967-017-1164-1.

27.

Immune Checkpoint Inhibitors in Gliomas.

Tan AC, Heimberger AB, Khasraw M.

Curr Oncol Rep. 2017 Apr;19(4):23. doi: 10.1007/s11912-017-0586-5. Review.

PMID:
28303490
28.

The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials.

Li BT, Barnes TA, Chan DL, Naidoo J, Lee A, Khasraw M, Marx GM, Kris MG, Clarke SJ, Drilon A, Rudin CM, Pavlakis N.

Lung Cancer. 2016 Dec;102:21-27. doi: 10.1016/j.lungcan.2016.10.004. Epub 2016 Oct 17.

29.

Reply to Dr Altundag from the authors of 'Management of breast cancer brain metastases; a practical review'.

Phillips C, Jeffree R, Khasraw M.

Breast. 2017 Aug;34:133. doi: 10.1016/j.breast.2016.11.026. Epub 2016 Dec 9. No abstract available.

PMID:
27955975
30.

Management of breast cancer brain metastases: A practical review.

Phillips C, Jeffree R, Khasraw M.

Breast. 2017 Feb;31:90-98. doi: 10.1016/j.breast.2016.10.006. Epub 2016 Nov 6. Review.

PMID:
27829201
31.

Ageing, Chronic Disease and Injury: A Study in Western Victoria (Australia).

Sajjad MA, Holloway KL, Kotowicz MA, Livingston PM, Khasraw M, Hakkennes S, Dunning TL, Brumby S, Page RS, Pedler D, Sutherland A, Venkatesh S, Brennan-Olsen SL, Williams LJ, Pasco JA.

J Public Health Res. 2016 Aug 19;5(2):678. eCollection 2016 Aug 19.

32.

Combining PARP inhibitors with radiation therapy for the treatment of glioblastoma: Is PTEN predictive of response?

Lester A, Rapkins R, Nixdorf S, Khasraw M, McDonald K.

Clin Transl Oncol. 2017 Mar;19(3):273-278. doi: 10.1007/s12094-016-1547-4. Epub 2016 Sep 21. Review.

PMID:
27655368
33.

Prioritization schema for immunotherapy clinical trials in glioblastoma.

Hodges TR, Ferguson SD, Caruso HG, Kohanbash G, Zhou S, Cloughesy TF, Berger MS, Poste GH, Khasraw M, Ba S, Jiang T, Mikkelson T, Yung WK, de Groot JF, Fine H, Cantley LC, Mellinghoff IK, Mitchell DA, Okada H, Heimberger AB.

Oncoimmunology. 2016 Feb 18;5(6):e1145332. doi: 10.1080/2162402X.2016.1145332. eCollection 2016 Jun. Review.

34.

Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.

Garber ST, Hashimoto Y, Weathers SP, Xiu J, Gatalica Z, Verhaak RG, Zhou S, Fuller GN, Khasraw M, de Groot J, Reddy SK, Spetzler D, Heimberger AB.

Neuro Oncol. 2016 Oct;18(10):1357-66. doi: 10.1093/neuonc/now132. Epub 2016 Jul 1.

35.

ICECREAM: randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours.

Segelov E, Waring P, Desai J, Wilson K, Gebski V, Thavaneswaran S, Elez E, Underhill C, Pavlakis N, Chantrill L, Nott L, Jefford M, Khasraw M, Day F, Wasan H, Ciardiello F, Karapetis C, Joubert W, van Hazel G, Haydon A, Price T, Tejpar S, Tebbutt N, Shapiro J.

BMC Cancer. 2016 May 31;16:339. doi: 10.1186/s12885-016-2389-8.

36.

Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring the KRAS G13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study.

Segelov E, Thavaneswaran S, Waring PM, Desai J, Robledo KP, Gebski VJ, Elez E, Nott LM, Karapetis CS, Lunke S, Chantrill LA, Pavlakis N, Khasraw M, Underhill C, Ciardiello F, Jefford M, Wasan H, Haydon A, Price TJ, van Hazel G, Wilson K, Simes J, Shapiro JD.

J Clin Oncol. 2016 Jul 1;34(19):2258-64. doi: 10.1200/JCO.2015.65.6843. Epub 2016 Apr 25.

PMID:
27114605
37.

A Discrete Choice Experiment to Examine the Preferences of Patients With Cancer and Their Willingness to Pay for Different Types of Health Care Appointments.

Wong SF, Norman R, Dunning TL, Ashley DM, Khasraw M, Hayes TM, Collins I, Lorgelly PK.

J Natl Compr Canc Netw. 2016 Mar;14(3):311-9. Epub 2016 Mar 8.

PMID:
26957617
38.

Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial.

Khasraw M, Lee A, McCowatt S, Kerestes Z, Buyse ME, Back M, Kichenadasse G, Ackland S, Wheeler H.

J Neurooncol. 2016 May;128(1):163-171. doi: 10.1007/s11060-016-2094-0. Epub 2016 Mar 2.

PMID:
26935578
39.

Use of targeted therapy in cancer patients in the end-of-life period: results from an Australian centre.

Wann A, Ashley D, Khasraw M.

Support Care Cancer. 2016 Jul;24(7):3023-8. doi: 10.1007/s00520-016-3124-3. Epub 2016 Feb 18.

PMID:
26887377
40.

Neuroendocrine tumors of the gastrointestinal tract and the role of cytotoxic chemotherapy.

Khasraw M, Ananda S, Michael M.

Expert Rev Anticancer Ther. 2016;16(4):391-401. doi: 10.1586/14737140.2016.1146135. Epub 2016 Feb 17. Review.

PMID:
26808925
41.

EpCAM Aptamer-mediated Survivin Silencing Sensitized Cancer Stem Cells to Doxorubicin in a Breast Cancer Model.

Wang T, Gantier MP, Xiang D, Bean AG, Bruce M, Zhou SF, Khasraw M, Ward A, Wang L, Wei MQ, AlShamaileh H, Chen L, She X, Lin J, Kong L, Shigdar S, Duan W.

Theranostics. 2015 Oct 20;5(12):1456-72. doi: 10.7150/thno.11692. eCollection 2015.

42.

Evolving management of low grade glioma: No consensus amongst treating clinicians.

Field KM, Rosenthal MA, Khasraw M, Sawkins K, Nowak AK.

J Clin Neurosci. 2016 Jan;23:81-87. doi: 10.1016/j.jocn.2015.05.038. Epub 2015 Oct 23.

PMID:
26601811
43.

Retrospective analysis of cancer survival across South-Western Victoria in Australia.

Wong SF, Matheson L, Morrissy K, Pitson G, Ashley DM, Khasraw M, Lorgelly PK, Henry MJ.

Aust J Rural Health. 2016 Apr;24(2):79-84. doi: 10.1111/ajr.12203. Epub 2015 Jun 29.

PMID:
26122852
44.

CDK4/6 inhibitors in breast cancer.

Dukelow T, Kishan D, Khasraw M, Murphy CG.

Anticancer Drugs. 2015 Sep;26(8):797-806. doi: 10.1097/CAD.0000000000000249. Review.

PMID:
26053278
45.

Antiangiogenic therapy for high-grade glioma.

Khasraw M, Ameratunga MS, Grant R, Wheeler H, Pavlakis N.

Cochrane Database Syst Rev. 2014 Sep 22;(9):CD008218. doi: 10.1002/14651858.CD008218.pub3. Review. Update in: Cochrane Database Syst Rev. 2018 Nov 22;11:CD008218.

PMID:
25242542
46.

Epidermal growth factor receptor-tyrosine kinase inhibitors in advanced squamous cell carcinoma of the lung: a meta-analysis.

Ameratunga M, Pavlakis N, Gebski V, Broad A, Khasraw M.

Asia Pac J Clin Oncol. 2014 Sep;10(3):273-8. doi: 10.1111/ajco.12231.

PMID:
25135201
47.

Patterns of care in adult medulloblastoma: results of an international online survey.

Cosman R, Brown CS, DeBraganca KC, Khasraw M.

J Neurooncol. 2014 Oct;120(1):125-9. doi: 10.1007/s11060-014-1525-z. Epub 2014 Jul 16.

PMID:
25026996
48.

Bevacizumab for the treatment of high-grade glioma: an update after phase III trials.

Khasraw M, Ameratunga M, Grommes C.

Expert Opin Biol Ther. 2014 May;14(5):729-40. doi: 10.1517/14712598.2014.898060. Epub 2014 Mar 22. Review.

PMID:
24655021
49.

Machine-learning prediction of cancer survival: a retrospective study using electronic administrative records and a cancer registry.

Gupta S, Tran T, Luo W, Phung D, Kennedy RL, Broad A, Campbell D, Kipp D, Singh M, Khasraw M, Matheson L, Ashley DM, Venkatesh S.

BMJ Open. 2014 Mar 17;4(3):e004007. doi: 10.1136/bmjopen-2013-004007.

50.

Brain metastases in breast cancer.

Sim HW, Morris PG, Patil S, Khasraw M.

Expert Rev Anticancer Ther. 2014 Feb;14(2):173-83. doi: 10.1586/14737140.2014.863468. Epub 2013 Dec 2. Review.

PMID:
24308683

Supplemental Content

Loading ...
Support Center